Personal tools
You are here: Home BRR Archive
Document Actions

BRR Archive

September 2009, Vol. 24 No. 8

Folotyn Receives FDA Accelerated Approval For Peripheral T-Cell Lymphoma. Poniard To Begin Data Analysis In Study Of Picoplatin For Small Cell Lung Cancer. FDA Signs Off On Phase III Design For OncoVEX In Head & Neck Cancer. Abbott, Pfizer Agree To Develop Test For NSCLC. Firm To Develop Online Educational Tools For NCCN Guidelines.

July 2009, Vol. 24 No. 7

Alimta Approved In Europe For Advanced Or Metastatic Non-Small Cell Lung Cancer. Boehringer Ingelheim Begins Phase III Trial Of Oral EGFR Inhibitor For NSCLC. AstraZeneca Submits Applications To FDA, EMA, For Vandetanib For NSCLC.

June 2009, Vol. 24 No. 6

Debiopharm, Moffitt Cancer Center Sign License Agreement For Small Molecule. US Oncology Launches iKnowMed Electronic Health Record System. CHMP Supports Javlor Approval For Urothelial Cancer. Merck, Oncothyreon Begin Phase III Trial Of Stimuvax. ASCO Commissions Study Of Non-Physician Health Workers.

May 2009, Vol. 24 No. 5

ODAC Recommends Accelerated Approval Of Arzerra For Refractory Leukemia. AlphaVax Completes Enrollment Of Phase I/II Trial Of CEA Cancer Immunotherapy. FDA Forms Task Force To Recommend Ways To Improve Agency's Transparency. Amgen, FDA Agree On One Element Of Pharmacovigilance Program For Aranesp.

April 2009, Vol.24 No. 4

Genentech Says Phase III Trial of Avastin in Colon Cancer Didn't Meet Endpoint. OncoGenex In Agreement With FDA on Prostate Cancer Trial Design. Genomic Health Says Validation Study Met Endpoint for Stage II Colon Cancer.

March 2009 Vol. 24 No. 3

FDA Approves Novartis Agent Afinitor For Advanced Renal Cell Carcinoma. Roche Completes Purchase Of Genentech For $46.8 Billion; R&D Stays In California. Infinity Begins Phase II Trial of Heat Shock Protein Inhibitor. Pharma & Biotech Invested $65 Billion In R&D From 2007. US Oncology Forms A CRO.

February 2009 Vol. 24 No. 2

US Oncology Earnings Down $370 Million, Company Cites ESA Safety Concerns. Amgen, Takeda Resume Enrollment In Phase III MONET1 Trial For NSCLC. Amgen Seeks FDA Approval For Denosumab In Bone Loss, And Osteoporosis Prevention. Cell Therapeutics Sells Interest In Zevalin Joint Venture.

January 2009, Vol. 24 No. 1

Roche Offer Lower Amount For Genentech Directly To Shareholders. Algeta Says Phase II Trials Demonstrate Alpharadin Can Prolong Bone Met Survival. YM BioSciences Gets Canadian Approval For Phase II Trials. FDA Tells Alfacell Another Trial Needed For Onconase; Firm Seeks Financing.

December 2008, Vol. 23 No. 11

FDA Approves Mozobil With G-CSF For Autologous Stem Cell Transplantation. Co-Payments To Rise As Access To Drugs Tightens For Patients On Medicare Part D. ImClone, BMS Apply To Broaden Erbitux To First-Line Treatment Of Advanced NSCLC. Merck Gives $1 Million To NCCN To Conduct Trials Of Zolinza.

November 2008, Vol. 23 No. 10

Eli Lilly Completes Purchase of ImClone, CEO Johnson To Retain Position. Cell Therapeutics' Pixantrone Achieves Primary Endpoint in Phase III Trial in Non-Hodgkin's Lymphoma.

October 2008, Vol. 23 No. 9

Firm Withdraws Ovarian Cancer Test After Receiving FDA Warning Letter. US Oncology Becomes Member Of RTOG. Eli Lilly, ImClone Approve Merger.

September 2008, Vol. 23 No. 8

US Oncology Begins Service Division To Provide Evidence-Based Cancer Care. Dendreon Begins Phase II Provenge Trial; Patients Randomized To Different Doses.

Log in


Forgot your password?
Google Ad Links
Google Ads
 

Powered by Plone CMS, the Open Source Content Management System

This site conforms to the following standards: